KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) EBT Margin: 2009-2025

Historic EBT Margin for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Sep 2025 value amounting to 46.97%.

  • Regeneron Pharmaceuticals' EBT Margin rose 684.00% to 46.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 36.11%, marking a year-over-year increase of 22.00%. This contributed to the annual value of 33.66% for FY2024, which is 164.00% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported EBT Margin of 46.97% as of Q3 2025, which was up 13.67% from 41.32% recorded in Q2 2025.
  • Regeneron Pharmaceuticals' EBT Margin's 5-year high stood at 2,122.20% during Q1 2022, with a 5-year trough of 22.28% in Q1 2024.
  • For the 3-year period, Regeneron Pharmaceuticals' EBT Margin averaged around 34.51%, with its median value being 33.42% (2023).
  • In the last 5 years, Regeneron Pharmaceuticals' EBT Margin spiked by 207,265bps in 2022 and then slumped by 209,507bps in 2023.
  • Quarterly analysis of 5 years shows Regeneron Pharmaceuticals' EBT Margin stood at 50.56% in 2021, then soared by 127,414bps to 1,324.70% in 2022, then crashed by 129,128bps to 33.42% in 2023, then crashed by 813bps to 25.29% in 2024, then surged by 684bps to 46.97% in 2025.
  • Its EBT Margin was 46.97% in Q3 2025, compared to 41.32% in Q2 2025 and 29.88% in Q1 2025.